Exercise and Type 2 Diabetes (InsITE)

This study has been completed.
Sponsor:
Collaborators:
American Diabetes Association
Information provided by (Responsible Party):
University of Colorado, Denver
ClinicalTrials.gov Identifier:
NCT00786019
First received: November 4, 2008
Last updated: March 6, 2013
Last verified: April 2012

November 4, 2008
March 6, 2013
May 2008
October 2011   (final data collection date for primary outcome measure)
Characterize the purported cardiac dysfunction during exercise in people with type 2 diabetes mellitus (T2DM),evaluate potential changes in cardiac function following 2 interventions: Three months exercise training and acute vitamin C administration. [ Time Frame: 3 years ] [ Designated as safety issue: No ]
To characterize the purported cardiac dysfunction during exercise in people with T2DM and evaluate potential changes in cardiac function following 2 interventions: Three months of exercise training and acute vitamin C administration. [ Time Frame: 3 years ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00786019 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Exercise and Type 2 Diabetes
Influence Of Endothelial Function On Central and Peripheral Causes Of Exercise Impairment In Type 2 Diabetes

The investigators have found that persons with type 2 diabetes have an impaired ability to perform exercise even without clinically apparent complications. The reasons for this marked abnormality are unknown but are important as the decreased ability to exercise could contribute to the decreased expenditure of physical activity frequently observed in this population and may potentially constitute an early marker of cardiovascular disease.

The investigators wish to evaluate the effects of impaired blood flow regulation on exercise capacity and whether the effects are more important in the heart or in the skeletal muscle tissue during exercise. In addition, the investigators are determining whether correcting these abnormalities by two methods of improving blood flow regulation (acutely infusing Vitamin C or three months of chronic exercise training) leads to improved blood flow regulation, improved heart and skeletal muscle tissue function and hence to better exercise capacity in person with type 2 diabetes. This information will provide a more mechanistic understanding of causes of abnormal exercise responses observed in person with type 2 diabetes as well as whether and to what degree responses are modifiable. Interventions that reverse the exercise defect may facilitate patient adherence to prescribed physical activity programs and potentially decrease cardiovascular mortality in this large segment of the population.

Not Provided
Interventional
Not Provided
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Health Services Research
Type 2 Diabetes
  • Behavioral: Exercise program
    Three month exercise program located at the Anschutz Medical Campus at I-225 and Colfax. The program runs three times per week for about an hour each session. Gym is open Monday - Saturday during specific hours (morning, noon, evening).
  • Drug: Ascorbic Acid (Vitamin C)
    During one exercise study visit, 0.06 g Vit C per kg fat-free mass per 100 ml of normal saline administered; Subjects will receive a bolus of 100mL Vit C solution given at 5ml/min over 20minutes followed by a "drip-infusion" given at 1.7ml/min.
    Other Names:
    • Ascorbic Acid
    • Vitamin C
Experimental: 1
All study subjects have ascorbic acid infusion during one exercise visit as well as a three month exercise training intervention.
Interventions:
  • Behavioral: Exercise program
  • Drug: Ascorbic Acid (Vitamin C)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
98
October 2011
October 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Men and women with uncomplicated Type 2 Diabetes
  • Healthy men and women without Type 2 Diabetes
  • Patients with Type 2 Diabetes may be taking metformin or sulfonylurea drugs to treat diabetes
  • Persons with history of hypercholesteremia if controlled with statins and/or diet
  • Patients who are moderately overweight (BMI 25-37.5)
  • Must be sedentary (defined as regular exercise < 2 times a week at a low to moderate level).
  • Patients with Hemoglobin A1c (HBA1C) <8%
  • Patients between the ages of 30 to 55 years
  • Premenopausal women.
  • Former smokers who have quit smoking for at least one year
  • Absence of comorbid conditions
  • Mild neuropathy is O.K. as long as it will not hamper exercise performance.
  • Resting systolic blood pressure (SBP) < 140, Resting diastolic blood pressure (DBP) < 90
  • Total Cholesterol < 205 Triglycerides < 250 low density lipoprotein (LDL) < 130
  • Control subjects with a normal A1C and fasting glucose

Exclusion Criteria:

  • People with T2DM taking oral medications, other than metformin or sulfonylurea drugs to control their diabetes.
  • Persons treated with insulin will be excluded
  • People who are currently smoking or have not quit for at least one year
  • Controls who have immediate family history of T2DM
  • Peri-menopausal or post-menopausal women.
  • Peripheral neuropathy
  • Total cholesterol > 205
  • Regional wall motion abnormalities
  • LV wall thickness ≥1.1 cm
  • Decreased contractility (fractional shortening <30%)
  • Ischemic heart disease (abnormal resting or exercise ECG)
  • Presence of angina that would limit exercise performance
  • Pulmonary problems that would limit exercise performance
  • Systolic blood pressure >140 mmHg at rest or >250 mmHg with exercise or diastolic pressure >90 mmHg at rest or >105 mmHg with exercise
  • Persons with autonomic insufficiency, assessed by measuring variation in RR intervals with cycled breathing and by presence of a >20 mm fall in upright blood pressure without a change in heart rate
  • Proteinuria (urine protein >200 mg/dl) or a creatinine > 2 mg/dl
  • Renal disease
Both
30 Years to 55 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00786019
07-1152, UL1TR000154
Yes
University of Colorado, Denver
University of Colorado, Denver
  • American Diabetes Association
  • National Institutes of Health (NIH)
Principal Investigator: Judith G Regensteiner, PhD University of Colorado, Denver
University of Colorado, Denver
April 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP